Suppr超能文献

相似文献

1
The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.
Cell Metab. 2014 Nov 4;20(5):910-918. doi: 10.1016/j.cmet.2014.10.001.
4
Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2541-6. doi: 10.1161/ATVBAHA.112.250571. Epub 2012 Aug 30.
6
The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
J Biol Chem. 2010 Jun 25;285(26):19720-6. doi: 10.1074/jbc.M110.123729. Epub 2010 Apr 28.
7
Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Nephrol Dial Transplant. 2014 Mar;29(3):538-43. doi: 10.1093/ndt/gft439. Epub 2013 Oct 28.
9
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Science. 2009 Jul 3;325(5936):100-4. doi: 10.1126/science.1168974. Epub 2009 Jun 11.

引用本文的文献

1
IMM-H007 promotes hepatic cholesterol and triglyceride metabolism by activating AMPK to attenuate hypercholesterolemia.
Acta Pharm Sin B. 2025 Aug;15(8):4047-4063. doi: 10.1016/j.apsb.2025.05.015. Epub 2025 May 21.
2
Is IDOL an Ideal Target for Treating Atherosclerosis?
Arterioscler Thromb Vasc Biol. 2025 May;45(5):672-674. doi: 10.1161/ATVBAHA.125.322661. Epub 2025 Mar 20.
3
IDOL Deficiency Inhibits Cholesterol-Rich Diet-Induced Atherosclerosis in Rabbits.
Arterioscler Thromb Vasc Biol. 2025 May;45(5):669-671. doi: 10.1161/ATVBAHA.125.322417. Epub 2025 Mar 6.
4
Lipid metabolism in myeloid cell function and chronic inflammatory diseases.
Front Immunol. 2025 Jan 22;15:1495853. doi: 10.3389/fimmu.2024.1495853. eCollection 2024.
7
Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health.
Nat Metab. 2024 Oct;6(10):1922-1938. doi: 10.1038/s42255-024-01126-4. Epub 2024 Sep 25.
8
Zebrafish mylipb attenuates antiviral innate immunity through two synergistic mechanisms targeting transcription factor irf3.
PLoS Pathog. 2024 May 13;20(5):e1012227. doi: 10.1371/journal.ppat.1012227. eCollection 2024 May.
10
Flindissone, a Limonoid Isolated from , Is an LXR Agonist.
J Nat Prod. 2023 Aug 25;86(8):1901-1909. doi: 10.1021/acs.jnatprod.3c00059. Epub 2023 Aug 1.

本文引用的文献

1
Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9.
Annu Rev Med. 2014;65:417-31. doi: 10.1146/annurev-med-022613-090402.
6
Lowering plasma cholesterol by raising LDL receptors--revisited.
N Engl J Med. 2012 Mar 22;366(12):1154-5. doi: 10.1056/NEJMe1202168.
8
FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors.
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20107-12. doi: 10.1073/pnas.1111589108. Epub 2011 Nov 22.
9
The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in humans.
J Clin Invest. 2011 Aug;121(8):3062-71. doi: 10.1172/JCI45504. Epub 2011 Jul 18.
10
The IDOL-UBE2D complex mediates sterol-dependent degradation of the LDL receptor.
Genes Dev. 2011 Jun 15;25(12):1262-74. doi: 10.1101/gad.2056211.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验